Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated clinical trial of Phase 1 P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T program Allogeneic CAR-T data to be presented at AACR in April 2024 describing activity of P-BCMA-ALLO1 in BCMA-experienced patients and comparison of lymphodepletion needs in heme vs. solid tumor settings P-FVIII-101 gene therapy data presented at ASH and Company to host Gene Therapy R&D Day April 17, 2024 SAN DIEGO , March 7, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM-rich allogeneic CAR-T to offer a differentiated and compelling efficacy, safety, and reliability profile that could compete with autologous CAR-T Plan to report clinical data updates for P-BCMA-ALLO1and P-MUC1C-ALLO1 allogeneic CAR-T programs at scientific meetings in 2024 Expect to dose first patient in the Phase 1 P-CD19CD20-ALLO1 trial in early 2024 Company to host Gene Therapy R&D Day April 17, 2024 SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlighted recent progress across the company's cell and gene therapy portfolio and provided updates on anticipated upcoming milestones. "In 2023, we made significant progress in delivering on the promise of our pipeline of allogeneic cell therapies through both substantial manufacturing advancements and compelling clinical data.

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones

Poseida Therapeutics is an oncology-focused biotech specializing in the development of cell therapies, particularly CAR T-cell approaches for multiple myeloma and acute leukemia. They have demonstrated promising early results in their clinical trials, with high response rates and manageable side effects. Particularly with respect to GvHD. The company also has gene therapy programs in development and has strong financial reserves to continue operations for several more quarters.

Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful

82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody Favorable emerging safety and reliability profile, with all (100%) intent-to-treat (ITT) patients receiving therapy, no GvHD or dose-limiting toxicities and low incidences of CRS and neurotoxicity observed (all ≤  Grade 2) Preliminary data show allogeneic TSCM-rich CAR-T cells trafficking to bone marrow, differentiating to cell-killing effector T cells and persisting at least 6 weeks Two additional poster presentations highlight advancements across the Company's cell and gene therapy programs and platforms Company to host webcast and conference call today at 11:00 AM PST SAN DIEGO , Dec. 10, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Celldex Therapeutics

Pulmonx

The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one's strategic collaboration with a multinational healthcare giant propels financial strength, unlocking accelerated milestones in key programs.

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare

Based upon progress in its allogeneic programs, the Company is announcing today acceleration and increased certainty of achieving upcoming milestones and payments related to the Roche Collaboration Closed strategic investment by Astellas Pharma in August 2023, bringing additional funding of $50 million Acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023, including early P-BCMA-ALLO1 data SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.   "In the third quarter, we continued to execute on our key priorities for 2023 while strengthening our financial position with a $50 million strategic investment from Astellas that closed in August 2023.

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023. Details for the Company's cell therapy presentations are as follows: Title: Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) Session Title and Location: 704.

Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy

Mark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema, Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO , Oct. 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D.

Poseida Therapeutics Announces Leadership Transition

CRISPR Therapeutics

Vertex Pharmaceuticals

In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities.

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

Poseida Therapeutics exhibits robust financials with Q2 2023 collaboration revenue surging to $20.01M and a recent $50M Astellas investment extending its cash runway. Despite stock underperformance, Poseida's diversified CAR-T pipeline shows momentum with FDA IND clearances and strategic collaborations, specifically with Roche. Investment recommendation shifts from "Buy" to "Strong Buy," predicated on Poseida maintaining its clinical efficacy and prudent financial management.

Poseida Therapeutics' Financial And Clinical Milestones Signal Upgrade To 'Strong Buy'

SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023.   "In the second quarter, we continued to make strong progress while sharpening our focus on our clinical pipeline and research efforts," said Mark Gergen, Chief Executive Officer of the Company.

Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

$50 million strategic investment validates Poseida's proprietary technology and cell therapy approach and supports strategic and operational plans Implementing enhancements to ongoing allogeneic programs based upon significant learnings; adjusting guidance on clinical data updates Extending cash runway guidance SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced a $50 million strategic investment by Astellas, which is comprised of the purchase of 8,333,333 shares of common stock at $3.00 per share for an aggregate purchase price of $25 million and an additional $25 million one-time payment for certain strategic rights, and provided a business update. "We are excited to announce a strategic investment by Astellas, a premier global pharmaceutical company that shares our strategic vision for the future of genetic engineering and cell and gene therapies.

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

Astellas Pharma Inc

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8 % of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an observer on the Poseida Board of Directors and Poseida's scientific advisory board TOKYO and SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, "Poseida") today announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy. Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8,333,333 shares of common stock of Poseida (approximately 8.8% of the outstanding common stock of Poseida) at $3.00 per share in a private placement and a one-time $25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20 SAN DIEGO, July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche. "We are pleased to receive IND clearance for P-CD19CD20-ALLO1, our third fully allogeneic CAR-T cell product candidate and the second therapy in our partnership with Roche for hematological malignancies that will enter the clinic.

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies

SAN DIEGO , June 26, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it is set to join both the broad-market Russell 3000® and small-cap Russell 2000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, according to a preliminary list of additions posted following the close of the U.S. markets on May 19, 2023. "We are pleased to be included in the Russell U.S. Indexes, which stands as a testament to the significant progress we have made across our cell and gene therapy portfolios," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes

SAN DIEGO , June 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, June 15, 2023 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.

Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

SAN DIEGO , May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET. A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023. Details for the presentations are as follows: Oral Presentation: Title: Expression and Activity of Human Factor VIII (hFVIII) Following Single and Repeat Administration of an Integrating Non-viral Gene Therapy in Multiple Mouse Models of Severe Hemophilia A Presenter: Denise Sabatino, Ph.D.

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis

Six presentations highlight significant advancements across the Company's Gene Therapy platform Preclinical data supports potential of P-OTC-101 to correct severe Ornithine Transcarbamylase Deficiency (OTCD) following a single dose Data presented establishes proof-of-concept for site-specific knock-in of a transgene using Cas-CLOVER™, Poseida's high-precision gene editing technology SAN DIEGO , May 18, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlights its two oral and four poster presentations on the Company's preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023. "We are excited to highlight multiple advancements across our gene therapy programs and platform technologies at ASGCT, which underscore the significant progress our company has made in the past year," said Brent Warner, President, Gene Therapy at Poseida Therapeutics.

Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.93 per share a year ago.

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates

Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema, Ph.D., as President, Cell Therapy, adding extensive oncology and allogeneic T cell immunotherapy experience to the Company's leadership team SAN DIEGO , May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

SAN DIEGO , May 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that six data presentations, including two oral presentations, highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually on May 16-20, 2023. Oral Presentations: Title: Preclinical Proof-of-Concept: A Novel Hybrid Gene Therapy Approach to Treat Severe Early-Onset Ornithine Transcarbamylase Deficiency Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases I Presentation Time: Thursday, May 18, 2023, 2:30 – 2:45 PM PST Location: Room 403 AB Abstract Number: 127 Title: Cas-CLOVER Technology Enables Precise Gene Editing and Site-Specific Transgene Insertion in Mouse Liver Session Title: Gene Targeting and Gene Correction: Liver Presentation Time: Thursday, May 18, 2023 3:00 – 3:15 PM PST Location: Room 515 AB Abstract Number: 157 Poster Presentations: Title: Demonstration of Human Factor VIII Expression and Activity Following Single and Repeat Dosing of a Non-Viral Integrating Gene Therapy  Session Title: Wednesday Poster Session Session Date/Time: Wednesday, May 17, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 638 Title: Development of a Novel Non-Viral Gene Therapy Platform Session Title: Thursday Poster Session Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 945 Title: Editing of a γ-Globin (HBG1/HBG2) cis-Regulatory Element in Human Hematopoietic Stem and Progenitor Cells Using Cas-CLOVER™ Technology Reactivates Fetal Hemoglobin Session Title: Thursday Poster Session  Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 1212 Title: Development and Optimization of Novel Super piggyBac®-Based Hybrid Gene Therapy Approach  Session Title: Friday Poster Session  Session Date/Time: Friday, May 19, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 1318 About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.

News for Poseida Therapeutics Stock (PSTX)